Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases

Neuro-Oncology

Volumn 15, Issue 6, 2013, Pages 650-655

  Miyatake, Shin Ichi ^a   Furuse, Motomasa ^a   Kawabata, Shinji ^a   Maruyama, Takashi ^b   Kumabe, Toshihiro ^a   Kuroiwa, Toshihiko ^c   Ono, Koji ^d  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

bevacizumab; boron neutron capture therapy; malignant gliomas; pseudoprogression

Indexed keywords

ALPHA TOCOPHEROL; AMINO ACID; ANTICOAGULANT AGENT; BEVACIZUMAB; CORTICOSTEROID; GADOLINIUM; METHIONINE C 11; NITROSOUREA; TRACER;

ANAPLASTIC OLIGOASTROCYTOMA; ARTICLE; ASTROCYTOMA; CANCER GROWTH; CASE REPORT; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CRANIOTOMY; DETERIORATION; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEMALE; GLIOBLASTOMA; HEMIPARESIS; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUTRON CAPTURE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RECURRENT CANCER; SPEECH DISORDER; TREATMENT FAILURE;

BEVACIZUMAB; BORON NEUTRON CAPTURE THERAPY; MALIGNANT GLIOMAS; PSEUDOPROGRESSION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; DISEASE PROGRESSION; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIATION INJURIES;

EID: 84878309472     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not020     Document Type: Article

References (18)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
2. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26: 2192-2197.
3. Brandsma D, Stalpers L, TaalW, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008; 9: 453-461.
4. Barth RF, Vicente MG, Harling OK, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012; 7: 146.
5. Kawabata S, Miyatake S, Kuroiwa T, et al. Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res (Tokyo). 2009; 50: 51-60.
6. Miyatake S, Kawabata S, Kajimoto Y, et al. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg. 2005; 103: 1000-1009.
7. Miyatake S, Kawabata S, Yokoyama K, et al. Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol. 2009; 91: 199-206.
8. Miyatake S, Kawabata S, Nonoguchi N, et al. Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas. Neuro Oncol. 2009; 11: 430-436.
9. Furuse M, Kawabata S, Kuroiwa T, Miyatake S. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol. 2011; 102: 471-475.
10. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebocontrolled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011; 79: 1487-1495.
11. Nonoguchi N, Miyatake S, Fukumoto M, et al. The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neurooncol. 2011; 105: 423-431.
12. Imahori Y, Ueda S, Ohmori Y, et al. Positron emission tomography- based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. Clin Cancer Res. 1998; 4: 1825-1832.
13. Imahori Y, Ueda S, Ohmori Y, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin Cancer Res. 1998; 4: 1833-1841.
14. Miyashita M, Miyatake S, Imahori Y, et al. Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas. J Neurooncol. 2008; 89: 239-246.
15. Nariai T, Ishiwata K, Kimura Y, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot. 2009; 67: S348-S350.
16. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009; 75: 156-163.
17. KhasrawM, Simeonovic M, Grommes C. Bevacizumab for the treatment of high-grade glioma. Expert Opin Biol Ther. 2012; 12: 1101-1111.
18. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007; 25: 2601-2606.